Journal of internal medicine
-
Randomized Controlled Trial Comparative Study
Romosozumab versus denosumab in long-term users of glucocorticoids: A pilot randomized controlled trial.
To compare the efficacy of romosozumab (ROMO) and denosumab (DEN) in prevalent long-term glucocorticoid (GC) users. ⋯ ROMO was superior to DEN in raising the spine BMD at Month 12 in chronic GC users. After switching to DEN, ROMO-treated patients continued to gain spine BMD to a greater extent than DEN until Month 24.